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ABSTRACT 
Objective: The present investigation was aimed to optimize the formula of paclitaxel-loaded liposomes (PTL) by using the application of response 
surface methodology (RSM). 
Methods: Paclitaxel-loaded liposome (PTL) was optimized by response surface methodology based on two parameters, namely, percent 
entrapment efficiency (% EE) and percent in vitro drug release at 12 h (% DR). The liposome formula was prepared using 32 factorial design, and the 
selected independent variables were, phospholipid (phospholipon 90G) and cholesterol (CH) concentrations. Nine formulas of paclitaxel-loaded 
liposome were prepared by thin film hydration technique (THF). The entrapment efficiency, in vitro release studies and drug content, were 
evaluated using on UV-visible spectrophotometer at λmax-230 nm. The developed PTL formulation vesicle morphology, particle size, polydispersity 
index (PDI) and zeta potential (ζ) were evaluated by Motic digital microscope and Malvern zetasizer respectively. 
Results: Using response surface methodology the estimated coefficient values obtained for independent variables in the regression equations, exhibited 
that the phospholipid (PL90G) and cholesterol (CH) molar concentration was observed to be highly influencing variables in optimizing % EE 
(86.67±0.67) and % DR (63.49±1.21). In the prediction of % EE and % DR values, the percent relative errors (PRE) was found to be low (–0.290%) and 
(0.058%) respectively. This suggests that design-developed model was found to be suitable for PTL formulations and thus, validate the model.  
Conclusion: Experimental results show that the observed responses were in close agreement with the predicted values and this demonstrates the 
reliability of the RSM in an optimization of % EE and % DR in paclitaxel liposomal (PTL) formulations. 
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Paclitaxel (PT) is a chemical compound isolated from the bark of 
Taxus brevifolia (northwest Pacific Yew Tree), empirical formula 
(C47H51NO14) and on the basis of characterization named it as Taxol 
[1]. It has the potential anticancer drug, based on previous reports, 
PT shows anticancer activities towards breast cancer [2], ovarian 
cancer [3], lung cancer [4] and pancreatic cancer [5]. However, PT 
exhibits poor aqueous solubility and permeability owing to 
biopharmaceutical classification system (BCS) class IV drug, which 
directs it to low bioavailability. Therefore, by consideration of these 
problems, there is a need to develop a novel formulation of such 
effective and efficient anticancer drug.  
For improving poor aqueous solubility and permeability of PT, a 
number of formulation strategies have been developed and used. 
Some of them were modified, due to some excipient–drug 
interactions. For improving the solubility, PT dissolved in a mixture 
of polyoxyethylated castor oil (Cremophore EL): dehydrated ethanol 
(1:1) ratio as a delivery vehicle. The formulation produced 
hypersensitivity and non-linear pharmacokinetic behavior after 
intravenous administration. The hypersensitivity reaction at the site 
of administration could be due to an inclusion of Cremophore EL [6-
7]. After that, the delivery vehicle was replaced with the addition of 
tween 80 alone or combination of tween 80: dehydrated alcohol, and 
diluted with aqueous media. The diluted formulation showed the 
precipitation of PT from solution due to low solubility [8]. These 
attempted techniques, with persistent low solubility problem, has 
been overcome by creating novel formulation with the aim of 
improving aqueous solubility, permeability, and bioavailability of 
PT. It includes novel oral formulation [9], novel PT self-emulsifying 
drug delivery system (SEDDS) [10], novel ligands based PT targeting 
formulation [11], micellar formulation [12], liposomal formulation 
[13], bioconjugates [14], dendrimers [15] and nanocarrier systems 
[16]. In all these formulation techniques the problem associated 
with PT was shown to be improved significantly. 
The liposome is emerging techniques for specialized drug delivery 
[17] and best suitable for lipophilic drug due to its 
biocompatibility and reducing drug toxicity, with maintaining 
efficacy of the anticancer drug for a maximum period of time. 
Some previous studies include asulacrine [18], docetaxel [19] and 
tamoxifen [20] with these approaches, their poor aqueous 
solubility and bioavailability were found to be improved. So, need 
to develop and optimize the paclitaxel-loaded liposomes (PTL) for 
effective anticancer treatment. In pharmaceutical technology, in 
the development and optimization of different pharmaceutical 
dosage forms, there are a high number of factors which influence 
the product characteristics. Therefore, complex, expensive and 
time-consuming formulation studies are often necessary for the 
development of a product with required and desired properties. 
The experimental design methodology is a strategy to use a 
smaller number of experiments and to avoid unnecessary 
experiments [21-22].  
Experiments were designed to determine the effect of the 
independent variables (factor) on the dependent variable 
(parameter/response) of a process or formulation. RSM, one of the 
designs of experiments, is a powerful tool for determining the 
relationship between a response and a set of quantitative involved 
factors. RSM is a technique used to find the optimum response by 
using the quadratic polynomial model [23]. The advantage of RSM is 
the reduced amount of experiments required, thereby reducing the 
cost of expensive analysis methods. The application of RSM is useful 
for understanding or mapping a region of the response surface, 
finding the variable level of optimum response, and selecting the 
process condition or formula to meet the specifications [24]. This 
research was carried out to optimize PTL formula with independent 
variables such as phospholipid (phospholipon 90G) concentration 
and cholesterol (CH) concentration. The optimum formula was 
obtained from RSM using 32 full factorial design. The optimization 
approach was applied to obtain desired % EE and % DR for PTL. 
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MATERIALS AND METHODS  
Materials 
Paclitaxel (PT), (purity>90%) was received as a gift sample from 
MAC-CHEM Products (India) Pvt. Ltd. Bhoisar, Thane, India. The 
phospholipids samples viz., Phospholipon 90G® (PL90G), 
Phospholipon 80H® (PL80H) and Phospholipon 90H®(PL90H) with 
purity >90%, was obtained as a free gift sample from Lipoid GmbH, 
Ludwigshafen, Germany. The solvents namely chloroform and 
methanol were purchased from Merck Ltd. Mumbai, India. 
Cholesterol (CH), potassium dihydrogen phosphate and sodium 
hydroxide pellets were obtained from Sigma Chemicals, Sigma-
Aldrich Corporation, St. Louis, MO. Chemical used in this work were 
of analytical grade (AR). 
Experimental design (32 full factorial design) 
To reduce the number of trials and attain the highest amount of 
information on product properties, the screening was done by 
applying full factorial design (32), systematically study the joint 
influence of the independent variables on the dependent variables. 
So, in this study two factors were evaluated, each at three levels 
and experimental trials was performed at all nine possible 
combinations. Amount of phospholipid (PL90G-1, 2 and 3 moles) 
was taken as the first independent variable (X1, w) and amount of 
cholesterol (CH-1, 2 and 3 moles) was selected as the second 
independent variables (X2, w) for liposomes. These variables varied 
at three levels, low level (-1), medium level (0), and high level (+1). 
All the calculations were done at milligram level. Amount of PT (10 
µM) and final formulation volume 15 ml was kept constant. Percent 
entrapment efficiency (% EE) (Y1) and percent in vitro drug release 
at 12 h (% DR) (Y2) were selected as dependent variables. Values of 
variables and batch codes are shown in table 1 and 2. Design 
Expert® DX 10.0.7.0 (Stat-Ease Inc., MN) license version software 
was used for the generation and evaluation of statistical 
experimental design [25-26].  
Preparation of paclitaxel-loaded liposomes (PTL) 
Liposomes were prepared by the thin film hydration method (TFH). 
The 10 µM PT (mol. wt., 853.9) constant for all batches and the 
required quantities of phospholipid (PL90G) (mol. wt., 758.07) and 
cholesterol (CH) (mol. wt., 386.67) were taken in a 100 ml round 
bottom flask and dissolved in 10 ml chloroform. All the batches were 
prepared according to the experimental design in table 1. 
Chloroform was evaporated using rotary vacuum evaporator 
(Model: PBV–7D, Vertical condenser, rotavap, superfitTM continental 
Pvt. Ltd., Mumbai, India) and kept overnight under vacuum. Then it 
was hydrated by 15 ml of phosphate buffer pH 7.4 for 1 h with 10 
min of extensive vortexing. The suspension of liposomes was 
sonicated in the water bath at 60 °C to reduce the size of liposomes. 
Non-incorporated PT was separated by ultracentrifuge at 10,000 
rpm for 30 min at 4 °C. The supernatant was then discarded and PT 
loaded liposomes in the precipitate were redispersed in required 
volume of phosphate buffer pH 7.4. This was transferred to vials and 
stored at 4 °C [27]. 
 
Table 1: 32full factorial design: factors, factor levels and responses for PTL formulation 
Factors (Independent variables) Factor levels used 
Low (-1) Medium (0) High (+1) 
Amount (moles) of phospholipid (PL90G) (X1, w) 1 2 3 
Amount (moles) of cholesterol (CH) (X2, w) 1 2 3 
Responses (Dependent variable) 
Y1 = Percent entrapment efficiency (% EE)  
Y2 = Percent in vitro drug release (% DR) 
 
Statistical analysis and optimization of formulation using RSM 
Response surface modeling and evaluation of the quality of fit of the 
model for the current study were performed employing Design 
Expert® DX 10.0.7.0 license version software [23-26, 30]. Polynomial 
models including linear, interaction and quadratic terms were 
generated for all the response variables using multiple linear 
regression analysis (MLRA). A second-order polynomial equation 
that describes the effect of independent factors on the response is 
expressed in the following forms:  
Linear model: Y = β 0+b1X1+b2X2 (1) 
2FI (interaction model): Y = β 0+β 1X1+β 2X2+β 12X1X2(2) 
Quadratic model = β 0+β 1X1+β 2X2+β 12X1X2+β 11X12+β 22X22(3) 
Where Y is the dependent variable; β 0 is the arithmetic mean 
response of the nine runs and βi (β1; β2; β12; β11 and β22) is the 
estimated coefficient for the corresponding factor Xi (X1, X2, X1X2, 
X1X1, and X2X2). The main effects (X1 and X2) represent the average 
result of changing one factor at a time from its low to high value. The 
interaction terms (X1X2) show how the response changes when two 
factors are simultaneously changed. The polynomial terms (X12 and 
X22) are included to investigate nonlinearity. The equations enable 
the study of the effects of each factor and their interaction over the 
considered responses. The polynomial equations were used to draw 
conclusions after considering the magnitude of coefficients and the 
mathematical sign they carry, i.e. positive or negative. A positive sign 
signifies a synergistic effect, whereas a negative sign stands for an 
antagonistic effect. The best fitting mathematical model was selected 
based on the comparisons of several statistical parameters, 
including the coefficient of variation (CV), the coefficient of 
determination (R2), adjusted coefficient of determination (Adjusted 
R2) and the predicted residual sum of square (PRESS), provided by 
Design Expert software. Among them, PRESS indicates how well the 
model fits the data and for the chosen model it should be small 
relative to the other models under consideration. Level of 
significance was considered at p<0.05. Mathematical relationships in 
the form of polynomial equations are generated using multiple 
linear regression analysis (MLRA) and used to find out the relative 
influence of each factor on the response. Analysis of variance 
(ANOVA) for the responses was performed to identify a significant 
effect of factors on responses and the model parameters were 
obtained. The relationship between the dependent and independent 
variables was further elucidated using contour and response surface 
plots. Two-dimensional contour plots and three-dimensional 
response surface plots resulting from equations were obtained by 
the Design Expert software. These plots are very useful in a study of 
the effects of two factors on the response at one time and predict the 
responses of dependent variables at the intermediate levels of 
independent variables. Subsequently, a numerical optimization 
technique by the desirability and graphical optimization technique 
by the overlay plot approach were used to generate the new 
formulation with the desired responses. An optimized formulation 
was developed by setting constraints (goals) on the dependent and 
independent variables. To validate the chosen experimental design, 
the resultant experimental values of the responses were quantitatively 
compared with those of the predicted values and calculated the 
percent relative error (PRE) by the following equation 5.  
% Relative error = … (4) 
Determination of percent entrapment efficiency (% EE) 
Purification of PTL formulation was done by the ultracentrifugation 
method [28]. To quantify the amount of entrapped PT, 2 ml of the 
vesicular dispersion was centrifuged at 10,000 rpm for 1 h at the 
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controlled temperature of 4 °C (Remi cooling centrifuge, Remi 
Elektrotechnik limited, India). Supernatant contains unentrapped 
drug was withdrawn and measured UV spectrophotometrically (at 
λmax-230 nm) (Model: SPECTRO 2060 PLUS, Analytical 
Technologies Ltd., Gujarat, India) against 30:70 ratio of methanol: 
phosphate buffer solution (PBS) (pH 7.4). All the determinations 
were made in triplicate. A calibration plot was produced by diluting 
stock solutions of PT with 30:70 ratio of methanol and PBS (pH 7.4). 
% EE was calculated and expressed as a percent of the available 
dissolved solute actually encapsulated. The amount of drug 
entrapped in liposomes was determined by equation 1. 
% entrapment efficiency (% EE) = (5) 
Percent in vitro drug release study (% DR) at 12 h. 
The in vitro drug release study for PT from different PTL formulation 
was carried out as per the procedure described by Utreja [29] with 
little modifications. In brief, the Franz diffusion cell apparatus was 
employed for this study. The apparatus is consisted of donor and 
receptor compartment, with an effective surface area for dissolution 
was (2.303 cm2). The dialysis membrane (LA395, Dialysis Membrane–
110 AV, flat width ~ 31.12 mm, Average diameter ~ 21.5 mm, and 
approximate capacity is ~ 3.63 ml/cm; HI media laboratories, Mumbai, 
India) was employed and pretreated as per the directions were given 
by the manufacturer. After proper pretreatment, the membrane was 
cut into desired size and shape, then mounted between the effective 
surface area of donor and receptor compartment. The PTL dispersion 
(2 ml) was placed over the membrane, accompanied by an addition of 
PBS (20 ml, pH 7.4) contain 0.1% tween 80 as dissolution media in the 
receptor compartment. The contents of receptor compartment were 
stirred at 100 rpm using magnetic stirrer at 37±1.0 °C. At specified 
time intervals, 2 ml aliquots were withdrawn from sampling port of 
apparatus, diluted suitably with fresh media and the absorbance of the 
resulting solution was read at 230 nm using UV-visible 
spectrophotometer (Model: SPECTRO 2060 PLUS, Analytical 
Technologies Ltd., Gujarat, India).  
Vesicle morphology study of liposomes 
The liposomes were mounted on glass slides and viewed under a 
Motic Digital Microscope (type DM-1802) for morphological 
observation after suitable dilution. The size analysis of PTL was 
examined at the magnification of (×40) using calibrated eyepiece 
micrometer. The images were recorded using Motic Image plus 2.0 
ML software, accompanying with the instrument.  
Determination of percent drug content 
One milliliter of dispersion was pipette from the PTL formulation 
and lysed with methanol. It was further diluted with 30:70 ratio of 
methanol: phosphate buffer solution (PBS) (pH 7.4) and sample 
were analyzed spectrophotometrically at λmax 230 nm for PT. [26] 
Determination of particle size, poly-dispersity index (PDI) and 
zeta potential (ζ) 
The size of liposomes was measured by dynamic light scattering with a 
Malvern zetasizer. Diluted (1:100) PTL dispersion was added to the 
sample cuvette and then cuvette is placed in zetasizer. The sample is 
stabilized for two minutes and reading was measured. The average 
particle size was measured after performing the experiment in 
triplicate. The zeta potential of developed PTL formulation was 
determined using Malvern zetasizer (Malvern zetasizer ver. 6.20, UK). 
The zeta potential was calculated by Helmholtz-Smoluchowski's 
equation from the electrophoretic mobility of liposomes at 25 °C [26]. 
RESULTS AND DISCUSSION 
Experimental design and data acquiring (32full factorial design) 
Full factorial design (32) was applied to optimize the PTL 
formulation. All nine batches of PTL were prepared according to the 
formulation variables as shown in table 2. Liposomes were obtained 
by the TFH method. RSM was exploited to estimate the influence of the 
molar ratio of PL90G and CH as independent variables and their 
interactions on the investigated responses (dependent variables; % EE 
and % DR). This experiment was aimed to identify considerable factor 
effect influencing the formulation performance and to set up to their 
excellent levels for the desirability of responses shown in table 2. 
Statistical analysis and optimization of formulation using RSM 
To evaluate the quantitative effects of factors (X1 and X2) and their 
levels low (-1), middle (0), and high (+1) on the preferred responses, 
the experimental values of the flux were analyzed by Design Expert® 
DX 10.0.7.0 license version software and mathematical models 
obtained for each response [25-26, 30-31]. The mathematical 
relationship generated using multiple linear regression analysis 
(MLRA) for the studied response variables (% EE and % DR at 12 h.) 
that were relating different response and independent variables are 
expressed as following polynomial equations (quadratic model).  
Y1 (% EE) = 76.63+3.10X1–9.44X2+3.18 X1X2–9.91X12+0.35X22 (6) 
Y2 (% DR12 h.) = 64.74+6.79X1–4.63X2–1.38X1X2–15.29X12–5.82X22 (7) 
The above equations expose the quantifiable effect of the 
independent variables, a molar ratio of PL90G and CH, on the 
responses such as % EE (Y1) and in vitro % DR at 12 h (Y2) as 
dependent variables. The fitted polynomial equation (quadratic 
model) related to % EE and percent in vitro % DR used to draw a 
conclusion after considering the coefficient and the mathematical 
sign it carries. i.e. positive and negative. The correlation coefficient 
(r2) of the quadratic model (0.9736) for response Y1 (% EE) and 
(0.9779) for response Y2 (% DR) was found to be significant. 
Response 1 (Percent entrapment efficiency) (% EE) 
Regression analysis of above equation (6) of response Y1 (% EE) 
revealed that the coefficient of β1 was positive and β2 was negative, 
this indicated that as PL90G (X1) increased the % EE increased but 
as we further increased the PL90G (X1) to higher level the % EE 
decreased and on increasing cholesterol (X2) the % EE decreased. 
The higher concentration of cholesterol leads to rigidity in the 
vesicles [26] which in turn decreased the % EE. The % EE of 
different liposomal batches was in a range of 51.68 to 86.67%. The 
maximum entrapment was observed in batch L4 (table 2) with the 
composition of PL90G: CH (2:1 molar ratio) (0,-1). 
 
Table 2: Composition 32 full factorial design with measured responses of PTL formulation 
Batches Variable level in 
coaded form 
Variable level in actual form Response variables 
X1 X2 Phospholipid (PL90G) 
in moles (X1, W) 
Cholesterol (CH) 
in moles (X2, W) 
Percent entrapment 
efficiency* (% EE)±SD 
Percent In vitro drug release* 
(12 h) (% DR)±SD 
L1 -1 -1 1 1 75.65±1.48 40.28±1.58 
L2 -1 0 1 2 64.23±0.82 43.68±0.98 
L3 -1 +1 1 3 51.68±0.75 32.39±1.02 
L4 0 -1 2 1 86.67±0.67 63.49±1.21 
L5 0 0 2 2 78.69±1.61 62.12±0.63 
L6 0 +1 2 3 65.23±1.17 56.98±1.33 
L7 +1 -1 3 1 77.12±1.53 56.32±1.42 
L8 +1 0 3 2 67.16±0.91 57.85±0.87 
L9 +1 +1 3 3 65.89±1.32 42.92±1.19 
*Values represented as mean±SD, n = 3, All baches contain drug 10 µM and 15 ml phosphate buffer (pH 7.4) for hydration. 
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Table 3: Analysis of variance (ANOVA) table of % EE 
Source Sum of squares df Mean squares F Value p-value Prob>F  
Model 829.57 5 165.91 22.14 0.0142 Significant 
X1–Phospholipid (PL90G) 57.72 1 57.72 7.70 0.0692  
X2–Cholesterol (CH) 534.68 1 534.68 71.36 0.0035  
X1X2 40.58 1 40.58 5.42 0.1024  
X12 196.35 1 196.35 26.20 0.0144  
X22 0.24 1 0.24 0.032 0.8693  
Residual 22.48 3 7.49    
Cor–total 852.05 8     
For estimation of the significance of the model, the analysis of variance (ANOVA) was executed, from the ANOVA data, the model F-value of response 
(Y1) (22.14) indicated that the model is significant shown in table 3. There is only a 1.42% chance that an F-value this large could occur due to noise. 
Values of “prob>F” less than 0.0500 indicate model terms are significant. In these case X2, X12 are significant model terms. Values greater than 
0.1000 indicate that model terms are not significant.  
 
Table 4: Parameter of selected quadratic model of % EE 
Std. dev. 2.74 R-squared (r2) 0.9736 
Mean 70.26 Adjusted R-Squared 0.9296 
C. V. % 3.90 Predicted R-Squared 0.7315 
PRESS 228.77 Adequate Precision 15.693 
The predicted R-squared value of 0.7315 is in reasonable agreement with the adjusted R-squared of 0.9296; i.e. the difference is less than 0.2. 
Adequate precision measures the signal to noise ratio. A ratio greater than 4 is desirable and the result of adequate precision was 15.693 indicates 
an adequate signal. So, this model can use to navigate the design space.  
 
The relationship between the dependent and independent variables 
was further elucidated using contour and response surface plots. 
The contour (fig. 1) and 3D response surface plots (fig. 2) of % EE 
clearly indicated that X1 and X2 highly influenced the response 1 (% 
EE). The change in % EE as a function of X1 and X2 was depicted in 
the form of contour and response surface plots based on full 
factorial design (32). So, middle level of X1 and low level of X2 was 








X1 = A: Phospholipid
X2 = B: Cholesterol



















Fig. 1: Counter plot showing the effect of phospholipid (PL90G) (X1) and cholesterol (CH) (X2) on % EE (Y1) of PTL 
 
Response 2 (Percent drug release at 12 h) (% DR) 
The effect on drug release at 12 h (% DR) (Y2) was observed to be 
significant (P<0.05) by ANOVA and the polynomial equation (7) 
revealed that the coefficient of β1 was positive and β2 was negative, 
this indicated that as PL90G (X1) increased the % DR increased and 
on increasing cholesterol (X2) the % DR decreased. The % DR 
increased with increased concentration of lipid and at a certain level 
the percent release is retarded above that and the release was 
decreased at higher levels of cholesterol. This is because cholesterol 
at higher levels makes the lipid bilayers more rigid and retards the 
release of the drug. This was evident by the higher cholesterol 
concentration of vesicles showed around 50 % of the release except 
for (L6) formulations. The L4 formulation found to have 63.43 % DR 
at 12 h (table 2) with the composition of PL90G: CH (2:1 molar ratio) 
(0,-1). At lower concentration of phospholipid and cholesterol, the 
drug release was very less due to the formation of stagnant layer 
[26].
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Fig. 2: Response surface plot showing the effect of phospholipid (PL90G) (X1) and cholesterol (CH) (X2) on % EE (Y1) of PTL 
 
Table 5: Analysis of variance (ANOVA) table of % DR at 12 h 
Source Sum of squares df Mean squares F Value p-value prob>F  
Model 948.33 5 189.67 26.53 0.0109 significant 
A-Phospholipid 276.62 1 276.62 38.70 0.0084  
B-Cholesterol 128.81 1 128.81 18.02 0.0239  
AB 7.59 1 7.59 1.06 0.3786  
A2 467.57 1 467.57 65.41 0.0040  
B2 67.74 1 67.74 9.48 0.0542  
Residual 21.44 3 7.15    
Cor Total 969.78 8     
From the ANOVA data, the model F-value of response (Y2) (26.53) indicated that the model is significantly shown in table 5. There is only a 1.09% 
chance that a model F-value this large could occur due to noise. Values of “prob>F" less than 0.0500 indicate model terms are significant. In these 
case, X1, X2, and X12 are significant model terms. Values greater than 0.1000 indicate that model terms are not significant.  
 
Table 6: Parameter of selected quadratic model of % DR at 12h 
Std. Dev. 2.67 R-squared (r2) 0.9779 
Mean 50.67 Adjusted R-Squared 0.9410 
C. V. % 5.28 Predicted R-Squared 0.8063 
PRESS 187.85 Adequate Precision 14.272 
The predicted R-squared value of 0.8063 is in reasonable agreement with the adjusted R-squared of 0.9410; i.e. the difference is less than 0.2. 
Adequate precision measures the signal to noise ratio. A ratio greater than 4 is desirable and result of adequate precision was 14.272 indicates an 








X1 = A: Phospholipid
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Fig. 3: Counter plot showing the effect of phospholipid (PL90G) (X1) and cholesterol (CH) (X2) on % DR at 12 h (Y2) of PTL 
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Fig. 4: Response surface plot showing the effect of phospholipid (PL90G) (X1) and cholesterol (CH) (X2) on % DR at 12 h (Y2) of PTL 
 
To envisage the effect of an independent factor on the response (Y2) 
the contour plot (fig. 3) and 3D-response surface plots (fig. 4) of % 
DR at 12 h shows the curvature with a change in the factor (X1 and 
X2). The plot was found to be curvilinear and indicated that a high 
value of % DR (63.43%) can be obtained for a combination middle 
level of X1 and low level of X2 factors.  
Desirability and overlay plot 
The aim of pharmaceutical formulation optimization is generally 
to find the levels of the variable that affect the chosen responses 
and determine the levels of the variable from which a robust 
product with high-quality characteristics may be produced. All the 
measured responses that may affect the quality of the product 
were taken into consideration during the optimization procedure. 
The % EE and % DR at 12 h were set out in the maximum criteria. 
Each response criterion was combined (overlay plot) to obtain the 
optimum value (fig. 5). The optimization results of this research 
can be seen in table 7. 
Validation of RSM results 
In order to evaluate the optimization capability of models generated 
according to the results of the RSM (32full factorial design), PTL 
formulation was prepared using the optimal process variables settings 
that X1 and X2 were equal to 2:1. The response Y1 (% EE) and Y2 (% DR 
at 12 h) obtained with predicted models and the experimental model 
were shown in table 8. The percent relative error was obtained using 
equation 4. The percent relative error (PRE) for response Y1 (% EE) 
and Y2 (% DR at 12 h) were found to be (–0.290) and (0.058) 
respectively. The maximum PRE value was (–0.290). However, the 
values were found to be<2 % and hence it confirmed the suitability of 
experimental design. The results showed good agreement on 
preparation properties with theoretical properties. 
  
Table 7: Characteristics of optimum formula 
Objects Phospholipid (PL90G) 
in moles (X1, W) 
Cholesterol (CH) 
in moles (X2, W) 
% EE  
(Y1, %) 
In vitro % DR at 12 h  
(Y2, %) 
Desirability  
Predicted 1.996 1.000 86.419 63.527 0.996 Selected 
Actual (L4) 2 1 86.67±0.67 63.49±1.21   
The optimization parameter of desirability was determined by regulating the optimum input variables to obtain one or more optimal parameters. 
The desirability value ranged between 0 and 1, where a value of 1 is perfect, i.e., the ideal parameter value [30]. The PTL desirability plot was shown 
in fig. 6. The optimizing desirability of PTL formulation was 0.996. This value was near to ideal value (1), meaning that the predicted parameters 
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Fig. 5: Overlay plot of % EE and % DR at 12 h 
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Fig. 6: PTL desirability plot 
 
Table 8: Validation of predicted and experimental PTL batch 
Response Experimental values Predicted value % Relative error (PRE) 
Y1 (% EE) 86.67±0.67 86.419 –0.290 
Y2 (% DR at 12 h) 63.49±1.21 63.527 0.058 
 
Vesicle morphology, percent drug content, particle size, PDI and 
zeta potential (ζ) of developed PTL formulation 
Vesicle morphology of developed PTL formulation was observed by 
Motic Digital Microscope (type DM-1802). The liposomes were 
spherical in shape with a smooth surface shown in fig. 7. 
The developed liposomal percent drug content was found to be 
98±1.0 %. (mean±SD, n = 3). Percent drug content indicated that the 
PT was uniformly distributed in vesicular dispersions and percent 




Fig. 7: Microphotograph of PTL by motic image plus 2.0 ML software 
 
  
Fig. 8: The particle size (A) and Zeta potential (B) of developed PTL formulation 
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The particle size (fig. 8A) and (ζ) zeta potential (fig. 8B) of developed 
PTL formulation was found to be 144.4 nm and (-) 22.6 mV. The 
polydispersity index was calculated as 0.224. The low polydispersity 
index indicates a narrow range of particle size distribution. The zeta 
potential was a reliable indicator in the prediction of stability of 
particles in a liquid medium and the possible interactions with other 
materials. The behavior (size and size distribution) of vesicles 
completely depended on the amount of selected variables were also 
reported [32].  
CONCLUSION 
In the present study, the response surface methodology i.e.32 full 
factorial design was successfully employed for the optimization of 
PTL formulations. The PTL was prepared by thin film hydration 
method. The results of above optimization study displayed that the 
phospholipids (PL90G) and cholesterol (CH) with a molar ratio (2:1) 
showed an enhancement in rate and extent of in vitro release of PT 
from design-optimized PTL formulations. Thus, we conclude that the 
proposed RSM could be useful for the preparation and optimization 
of paclitaxel-based liposomal formulations.  
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